Last reviewed 2026-04-20 · How we verify

1.5% levofloxacin ophthalmic solution

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% (PHASE1, PHASE2)
• The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% (PHASE1, PHASE2)
• Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery (PHASE4)
• Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators (PHASE4)
• Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• 1.5% levofloxacin ophthalmic solution CI brief — competitive landscape report
• 1.5% levofloxacin ophthalmic solution updates RSS · CI watch RSS
• Santen Inc. portfolio CI